|Protocol #||Sponsor||Protocol Title|
|NCT02358031||Merck Sharp & Dohme Corp.|
|A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)|
EMR 100070-001, 2013-002834-19
|A Phase I, Open-label, Multiple-Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications|
|NCT02605967||Novartis Pharamaceuticals |
|A Phase II, Open-label, Randomized Controlled Study of PDR001 in Patients with Moderately Differentiated/Undifferentiated Locally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma Who Progressed on Standard Treatment|
Northwest Georgia Oncology Centers‘ (NGOC) physicians work with specialty teams of ENT surgeons and radiation oncologists to provide expert care in cancer of the head and neck.